C

Cencora

Global pharmaceutical distribution and services provider

Customer Account Setup and Credit Intern

Summer 2027Updated on 10/5/2026
No salary listed
Internship
Bachelor's, Associate's
Carrollton, TX, USA
HybridOne to two days per week in the office; the office may move to Dallas.
No H1B Sponsorship

About the job

Requirements
  • Currently pursuing an associate’s or bachelor’s degree in finance, accounting, business, data analytics, or a related field.
  • Coursework or experience in credit analysis, finance, accounting, business law, or data analysis.
  • Experience reviewing business documents or working with customer or financial data.
  • Basic to intermediate Microsoft Excel skills, including the ability to create and use basic formulas, build pivot tables, and work effectively with large data sets.
  • Working knowledge of Microsoft Office applications, including Word, Outlook, and PowerPoint.
  • Must not require sponsorship to work in the United States now or in the future.
  • Strong attention to detail and commitment to accuracy.
  • Sound analytical, critical-thinking, problem-solving, and organizational skills.
  • Clear and professional written and verbal communication skills.
  • Ability to manage multiple assignments, meet deadlines, and follow established procedures.
  • Ability to work both independently and collaboratively across multiple teams.
  • Professional judgment and discretion when handling confidential customer and financial information.
  • Willingness to learn new systems, processes, and regulatory requirements.
Responsibilities
  • Rotate across three customer account setup teams to learn end-to-end onboarding processes and provide day-to-day operational support.
  • Spend at least 50% of the internship supporting the Credit team.
  • Run and review credit reports and other available financial information.
  • Perform initial credit reviews, identify relevant risks or missing information, and prepare findings or recommendations for team review.
  • Assist with preparing, filing, tracking, and maintaining Uniform Commercial Code lien documentation in accordance with established procedures.
  • Validate customer onboarding documents for completeness, accuracy, and compliance with internal requirements.
  • Enter, update, and maintain customer and account information in applicable systems and trackers.
  • Use Excel to organize, reconcile, analyze, and summarize large data sets, including creating basic formulas and pivot tables.
  • Research and resolve routine data or documentation discrepancies, escalating issues when appropriate.
  • Prepare status updates, reports, and process documentation to support team activities and continuous improvement efforts.
  • Communicate professionally with internal partners and, when needed, customers to obtain information or clarify documentation.
  • Support additional account setup, credit, and onboarding projects as assigned.
Desired Qualifications
  • Rising sophomore, junior, or senior at the time of the internship is preferred.
  • Familiarity with Uniform Commercial Code filings, customer onboarding, credit processes, or enterprise systems is helpful but not required.

About the company

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 Q3 revenue rose 5.1% to $84.8 billion; EPS beat estimates.
  • Cencora repurchased $1 billion shares in Q3 2026 and raised fiscal 2026 guidance.
  • June 17 and September 2, 2026 launches expand high-growth specialty and cell-therapy services.

What critics are saying

  • March 31, 2026 accrued opioid liability remained $4.3 billion, payable over 13 years.
  • Baltimore’s October 2025 verdict was vacated in April 2026, but opioid litigation persists.
  • ASP rule changes and specialty-logistics competition can compress margins and derail oncology economics.

What makes Cencora unique

  • Cencora embeds inside oncology through OneOncology and RCA, strengthening provider switching costs.
  • June 17, 2026 Nucleus and September 2, 2026 CGT Enablement deepen workflow integration.
  • Global distribution scale and specialty services create a rare pharma-plus-services moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.